Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy

Annele Sainio1 and Hannu Järveläinen1,2*

Abstract

Tumour cells create their own microenvironment where they closely interact with a variety of soluble and non-soluble molecules, different cells and numerous other components within the extracellular matrix (ECM). Interaction between tumour cells and the ECM is bidirectional leading to either progression or inhibition of tumourigenesis. Therefore, development of novel therapies targeted primarily to tumour microenvironment (TME) is highly rational. Here, we give a short overview of different macromolecules of the ECM and introduce mechanisms whereby they contribute to tumourigenesis within the TME. Furthermore, we present examples of individual ECM macromolecules as regulators of cell behaviour during tumourigenesis. Finally, we focus on novel strategies of using ECM macromolecules as tools or targets in cancer gene therapy in the future.

Keywords: Extracellular matrix, Macromolecules, Tumour microenvironment, Cancer, Gene therapy

Introduction

Normally, the extracellular matrix (ECM) is composed of a dynamic 3D network of macromolecules, particularly collagens, elastin, proteoglycans (PGs) and hyaluronan (HA), and other non-collagenous matrix glycoproteins [1,2]. In the ECM there are also ECM degrading enzymes as well as a variety of soluble factors such as growth factors, chemokines and cytokines [1]. Furthermore, within the ECM there are several cell types including fibroblasts, adipocytes, epithelial and endothelial cells as well as different immune cells [3]. The principal function of the ECM is to maintain normal architecture and homeostasis of a particular tissue. The composition of the ECM is unique to each tissue and it undergoes constant enzymatic and non-enzymatic modifications and remodeling processes through a biophysical dialogue between its components [4]. These modifications and remodeling processes result in versatile microenvironments, “niche”, which in turn vitally regulate the behaviour of the cells within the ECM [5].

In cancer, the malignant cells are known to create their own tumour microenvironment (TME) which crucially affects both the malignant cells themselves and all other cells within the ECM [5-8]. As tumours are composed of a mixture of different cells, the effect of TME on the malignant cells can vary depending on the cell type in question. For example, cancer stem cells (CSCs), which usually form a small portion of the whole tumour, can create their own “CSC niche” within the TME which then regulates their proliferation and also causes a barrier to anticancer therapeutics [9]. Besides CSCs, in the tumours there are also several other cell types like cancer-associated fibroblasts (CAFs), tumour associated macrophages (TAMs) and neutrophils (TANs). The presence of inflammatory cells emphasizes the importance of inflammation in tumourigenesis [3]. Regarding TAMs, two subtypes, namely M1 (tumour preventing) and M2 (tumour promoting) have been recognized [10]. Similarly, TANs have been shown to exhibit two separate phenotypes, N1 (phenotype with antitumoural properties) and N2 (protumoural phenotype) [11]. These cells represent the double role of autoimmunity with both pro- and antitumoural effects [12]. The above mentioned cells together with CAFs are able to variously secrete ECM macromolecules (e.g., collagen type I, biglycan, versican, fibronectin) as well as growth factors and cytokines [e.g., vascular endothelial growth factor (VEGF), tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6)] contributing to tumourigenesis [13-17].
Apart from the ECM macromolecules, growth factors and cytokines mentioned above, there are other essential groups of molecules regulating tumour initiation and progression. For example, overexpression of ECM degrading enzymes such as matrix metalloproteinases (MMPs) can promote tumourigenesis. Indeed, in ovarian cancer the expression of MMP-2 and MMP-9 has been shown to correlate with poor survival indicating increased disseminating capability of cancer cells [18,19]. In addition to MMPs, other members of the metzinrin superfamily such as a disintegrin and metalloproteinases (ADAM) and ADAM with thrombospondin motifs (ADAMTS) are known to be critically involved in ECM turnover and remodeling during tumourigenesis [20-22]. The same applies to the family of lysyl oxidase (LOX) enzymes and transglutaminases that also represent central molecules in regulating ECM organization and tumour progression [23,24].

Furthermore, cell membrane adhesion molecules called integrins are importantly involved in the development of tumours. For example, in prostate cancer metastasis integrin αvβ6 expression has been shown to induce the expression of MMP-2 which in turn mediates osteolysis via its matrix degrading activity [25]. Certainly, other molecules and mechanisms whereby TME is involved in tumourigenesis could be presented [5,26,27].

Tumour progression also requires angiogenesis. Normally angiogenesis is strictly regulated. However, in the TME various cells can overexpress angiogenesis stimulating growth factors like VEGF ensuring oxygen and nutrient delivery to the growing tumour cell mass [28,29]. In addition to certain growth factors, specific ECM macromolecules by themselves are known to be able to regulate angiogenesis [30]. As the central role of the ECM and its components in tumourigenesis has become a recognized fact, to study the regulatory functions of the ECM macromolecules in the TME is of vital importance [31]. In this review we will focus on the ECM macromolecules in cancer and on the possibility to exploit them as novel therapeutic tools or targets in cancer gene therapy.

**Review**

**ECM macromolecules and cancer**

As mentioned in the beginning, ECM macromolecules can be categorized into four main groups: collagens, elastin and microfibrillar proteins, PGs and HA, and other non-collagenous matrix glycoproteins [2]. From these main groups, a subclass of secreted proteins, so-called "matricellular proteins” can be segregated [32-34]. They comprise a group of ECM macromolecules including thrombospondin- 1 and -2, SPARC (secreted protein, acidic and rich in cysteine), tenasin C (TN-C) and osteopontin [34]. The matricellular proteins do not directly participate in the formation of structural elements but are rather involved in the modulation of cell-matrix interactions and cell function. For example, TN-C is often associated with increased invasiveness of tumour cells [35]. On the basis of the ability of individual ECM macromolecules to form fibers, classification into fiber-forming and interfibrillar matrix molecules can also be made. Most of these ECM macromolecules have been shown to be variously associated with cancer as described below.

Collagen is the most prominent structural protein of the ECM and 28 collagen types have been identified [36]. Different collagens, particularly types I and III are often associated with cancers such as breast and pancreatic cancers resulting in increased stromal collagen accumulation and promotion of cancer progression [37-40]. In breast cancer, collagen accumulation together with increased expression of small leucine-rich proteoglycans (SLRPs) decorin and lumican has been shown to correlate with increased mammographic density [41]. Also degradation of specific collagens has been observed during metastasis and the resulting collagen fragments can recruit e.g. TAMs whose abundance in tumours predicts poor prognosis [39,42]. On the other hand, degradation of collagen type XVIII resulting in the formation of endostatin causes inhibition of angiogenesis and thereby retards tumour growth [43]. Furthermore, some collagens such as type XXI and XXIV have been referred to have prognostic value in certain cancers [44].

Similarly to the richness of collagen types, over 30 mostly extracellular PG species have been identified [45,46]. With few exceptions PGs comprise a protein core to which one or more glycosaminoglycan (GAG) side chains are covalently linked. Many of the PGs, like certain family members of the SLRPs have been shown to be involved in the organization of the ECM [47]. For example, the SLRPs decorin, biglycan, fibromodulin and lumican are centrally involved in the regulation of collagen fibrillogenesis [48-51]. The above mentioned SLRPs are also variously involved in tumourigenesis. Especially decorin has a recognized regulatory role in tumour development, most notably via its ability to down regulate several members of the receptor tyrosine kinase (RTK) family members such as the epidermal growth factor receptor (EGFR) [52-54]. Furthermore, decorin can regulate the activity of the Met receptor, i.e., the receptor for hepatocyte growth factor, and the insulin-like growth factor receptor 1 (IGF-IR) [55,56]. Interestingly, decorin can also regulate tumour angiogenesis by reducing the production of e.g., VEGF [57,58]. Other mechanisms whereby decorin contributes to tumour growth will be discussed later on. Regarding lumican, it has been shown to variously modulate proliferation, migration and adhesion of cancer cells. For example, inhibition of tumour cell migration by lumican has been shown to be mediated...
via its interaction with α2β1 integrin [59]. Similarly to decorin, lumican can also regulate cancer associated angiogenesis [60].

Hyaluronan is a versatile non-sulfated GAG that consists of repeating D-glucuronic acid and N-acetyl-D-glucosamine disaccharides. It has a widely recognized tumour promoting role in several cancer types such as prostate, ovarian and breast cancers via activating e.g., CD44 and RHAMM (receptor for hyaluronan-mediated motility) mediated signaling pathways including NFκB and mitogen-activated protein kinase (MAPK) pathways [61-63]. Indeed, its stromal accumulation is typical of progressed and undifferentiated tumours predicting poor prognosis [64-66].

Non-collagenous matrix glycoproteins like fibronectin have also been linked with cancers such as lung cancer, where its overexpression correlates with invasive and metastatic phenotype [67]. Fibronectin can bind to other ECM molecules and integrins including αvβ3 and thereby regulate among its other functions cell adhesion and Epithelio-Mesenchymal Transition (EMT) [68]. Different ECM molecules may also exist as tumour promoting splice variants as has been described e.g. for TN-C in breast cancer [69].

En bloc, ECM macromolecules are of central importance in cellular biology and they must act in concert in a finely regulated manner to maintain homeostasis and cellular functions within tissues and organs [70]. When the ECM is affected by inherited defects or its components are dysregulated, the proper 3D network of the matrix is lost and the cell-matrix interactions are hampered leading to or enabling different disease processes. Below, we will present some mechanisms whereby ECM macromolecules promote or alternatively inhibit tumourigenesis.

**ECM macromolecules as regulators of tumourigenesis within the TME**

Remodeling of the ECM is considered one of the earliest steps in the formation of TME which involves most ECM proteins [71]. Today we understand that there is an interaction between ECM macromolecules and cancer cells within each specific TME that can either facilitate or counteract the growth of solid tumours [9,72,73]. The TME can also restrict drug delivery to malignant cells [3,9]. As different ECM molecules possess central functional roles in various cellular events crucial in tumourigenesis like proliferation, adhesion, migration, survival and differentiation of the cells, they represent potential and novel targets and tools for pharmacotherapy [2].

With the help of the TME, cancer cells are able to exploit various mechanisms that can increase their malignancy and survival, e.g. they use autophagy to survive in nutrient-limited and hypoxic microenvironments [74]. On the other hand, autophagy has also been linked to suppression of tumourigenesis through elimination of p62 in tumour cells [75]. Interestingly, the SLRP decorin has been found to act as a regulator of endothelial cell autophagy which results in the inhibition of angiogenesis and suppression of tumour growth [76]. More precisely, soluble decorin induces the expression of Peg3, a transcription factor usually silenced in cancer and causes inhibition of endothelial tubulogenesis and cell migration [77]. In addition to regulating autophagy, decorin is able to cause mitostatin-dependent mitophagy by inducing the expression of mitostatin via the Met receptor (the receptor for hepatocyte growth factor) resulting in concurrent decrease in VEGF-A transcription in breast cancer cells and subsequently inhibition of angiogenesis [78].

Other mechanisms that can be exploited by cancer cells via ECM macromolecules are Epithelia-Mesenchymal Transition (EMT) and its reverse process called Mesenchymal-Epithelial Transition (MET) [79]. The epithelial plasticity is a central part of normal development, but its regulators including myc, growth factors such as TGF-β, and β-catenin can be misexpressed in cancers like breast [80], ovarian [81] and colon [82] cancers, respectively. This plasticity provides tumour cells with phenotypes which enable them to escape from the primary tumour. As breast cancer cells among other malignant cell types are known to secrete TN-C, an ECM macromolecule often associated with the invasive front of tumours [83,84], its expression together with the production of TGF-β1 can cause the malignant cells to undergo EMT [85]. Furthermore, integrins αvβ1 and αvβ6 are able to independently participate in this TN-C-induced EMT-like change [86]. The EMT also involves several other molecules including cadherins, focal adhesion molecules and proteolytic enzymes, e.g. MMPs [87]. All the above mechanistical possibilities have to be taken into account when novel therapies focusing on the ECM are developed.

**ECM macromolecules as tools or targets in gene therapy**

As discussed above, marked quantitative changes in the composition of the ECM macromolecules are a typical feature of different types of cancer. However, the distinction must be made whether these changes are the cause of the malignant disease or the result of it [7]. In spite of this, because individual ECM macromolecules can significantly influence cell behaviour and disease processes, modulation of the ECM composition provides a rational way to be used as an optional novel therapy in diseases like cancer. This modulation could be achieved with a number of approaches including gene therapy where specific ECM macromolecules are used as tools or targets.

**Challenges using gene therapy**

Generally, the development of gene therapy sets several challenges [88]. These challenges include choice of the vector to deliver the gene, the delivered gene itself and the route of administration. Furthermore, viruses must
target diseased cells with enough large numbers to achieve wanted effects and at the same time with minimal destruction of the normal cells [89,90]. Timing of the gene delivery is also a critical issue to be considered because several tumours undergo marked temporal changes, as can be seen e.g. during the initiation and progression of pancreatic cancer [91]. Some tumour types like pancreatic cancer can also contain vast amounts of HA resulting in exceptionally high interstitial fluid pressure in solid tumour tissue, which in turn can prevent perfusion and diffusion of small molecule therapeutics [92]. In addition to the above challenges, alterations in the chemomechanical environment of cancer cells has to be recognized [5,93-95].

When gene therapy for cancer using or targeting ECM macromolecules is developed, the challenges can become even more sophisticated. For example, regarding the timing of gene therapy it is noteworthy to take into account that collagen expression has been discovered to have a dual role in tumour progression; different collagen types can either restrict or promote tumour development depending on the stage of the tumour [6,96]. Furthermore, phenomenon known as desmoplastic reaction, i.e., the formation of a sclerotic stroma around the cancer cell population due to the overexpression of certain collagen types can make the gene targeting problematic [7]. This dense fibrotic deposition is typical of cancers like colorectal [97,98], pancreatic [99,100] and liver [101] cancers. In addition to the possible increased amount of ECM macromolecules around the cancer cells, most cancers are of epithelial origin and still maintain intercellular junctions despite their de-differentiated nature further restricting gene targeting [102]. However, it is possible to overcome these challenges as is discussed in the following two sections. Thus, gene therapy may have a promising future.

**Strategies to overcome ECM macromolecule formed barrier in cancer treatment using gene delivery**

Excess accumulation of the ECM macromolecules in the TME plays a critical role in blocking the transport of therapeutics to the target cells. Specifically, fibrillar collagen and collagen-proteoglycan bonds can form a major limit to the delivery of gene vectors [103,104]. Even nanomedicine utilizing nanoparticles can confront this same problem [105]. Regarding drug penetration to the tumour, the use of ECM macromolecules in gene therapy could provide a solution. For example the use of decorin containing replicating oncolytic adenovirus can increase drug penetration to solid tumours leading to a dramatic anti-tumour effect [102]. This beneficial effect of decorin gene delivery has been suggested to be based on decreased expression of other ECM molecules within the tumour tissue [102]. The physical barrier formed by ECM macromolecules is also possible to overcome by the administration of hyaluronidase (HAase) or collagenase containing oncolytic adenoviruses, which have been found to lead to significant tumour regression [106-108]. Additionally, the use of HAase can enhance the action of immune effector cells via degradation of the HA formed halos around cancer cells like adherent fibrosarcoma cells [109]. Treatment with HAase has also been shown to stimulate hematopoiesis and to increase the number of neutrophils in the peripheral blood [110].

![Figure 1 Schematic representation of the desired effects of ECM-based gene therapies in cancer.](http://www.molcelltherapies.com/content/2/1/14)
Applying the same ECM degrading principle with other enzymes such as MMPs can be valuable [111]. For example, adenoviral expression of MMP-8, which breaks down collagen type I, II, and III, is a potential strategy for improving ECM hindered drug penetration or viral spread [112]. Apart from degrading excess ECM in the tumour matrix, reducing ECM production or modifying ECM organization by means of pharmacological intervention offers potential strategies to improve drug penetration [113,114]. This kind of manipulation of the tumour matrix structure can be considered as “matrix normalization” [105,113,114].

Inhibition of tumour progression using selected ECM macromolecules via gene delivery

A myriad number of ECM macromolecules are known to be involved directly or indirectly in tumourigenesis [5]. This provides several possibilities for using ECM macromolecules as tools in gene therapy. For example, expression of human decorin cDNA via adenovirus mediated transfection has been demonstrated to induce specific and even distant apoptosis of cancer cells demonstrating a direct antitumourigenic effect of decorin [115,116]. In addition to decorin, there are other PGs such as lumican and its core protein called lumcorin that have been found to possess antitumourigenic functions and could therefore be used as a chosen molecule in gene therapy [117-119]. Furthermore, human fibronectin containing recombinant adenovirus has been shown to be a promising strategy as a novel gene therapy against metastatic breast cancer via its inhibitory effect on adhesion of cancer cells to ECM molecules [120]. Additional ECM-based gene therapy strategies also exist. Regarding HA, interactions between HA and its major cell surface receptor, CD44, have raised interests on the basis of influencing on CD44 variants (CD44v) of cancer cells [121]. For example, cell-specific delivery of shRNA (short hairpin RNA) targeting HA-CD44v6 has been shown to lead to marked inhibition of tumour growth in mice [122]. In the case of collagen, particularly the 20 kDa C-terminal cleavage product of collagen type XVIII (endostatin) provides a very potent candidate in gene therapy in the future [43]. Endostatin is able to markedly inhibit not only angiogenesis but also lymphangiogenesis [123]. Adenoviral transfection carrying endostatin to bladder cancer cells in mouse models has already been shown to significantly decrease tumour progression via angiogenesis inhibition [124]. In theory, gene delivery of specific ECM macromolecules such as collagen and decorin could also be applied to encapsulate the tumour mass, thus possibly restricting tumour growth and metastasis [7,58]. A summary of the desired effects of different ECM-based gene therapies on tumours is presented in Figure 1.

Conclusions

The ECM has a recognized role in the regulation of key cellular functions such as adhesion, proliferation, migration and apoptosis. Also the differentiation of normal and cancer associated cells is known to be highly dependent on the interaction of the cells with their microenvironment. Therefore, the ECM is critically involved in various disease processes including tumourigenesis where significant changes in the composition and structure of the ECM can be observed. Although it has not been clearly established whether the observed ECM changes are the cause or the result of various diseases including cancer, strategies to modulate the structure of the ECM offers therapeutic possibilities. These could be achieved e.g. via gene therapy utilizing specific ECM macromolecules as tools and/or targets. As discussed in this review, the current literature offers solid rationale to the development of gene therapies focusing primarily on the ECM. However, several challenges must still be resolved. These include choice of the vector and the delivered gene itself, timing of the delivery and route of administration. Nevertheless, ECM-based gene therapies form a very attractive and promising field of research that is likely to advance novel treatments of cancer in the future.

Abbreviations

ADAM: A disintegrin and metalloproteinases; ADAMTS: A disintegrin and metalloproteinases (ADAM) with thrombospondin motifs; CAF: Cancer-associated fibroblast; CD44v: CD44 variants; CSC: Cancer stem cells; ECM: Extracellular matrix; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; GAG: Glycosaminoglycan; HA: Hyaluronan; HAase: Hyaluronidase; IGF-IR: Insulin-like growth factor receptor I; IL-6: Interleukin 6; MAPK: Mitogen-activated protein kinase; MET: Mesenchymal-epithelial transition; Met: Mesenchymal-epithelial receptor I; IL-6: Interleukin 6; MAPK: Mitogen-activated protein kinase; MET: Mesenchymal-epithelial transition; Met: Mesenchymal-epithelial transition (Met) receptor/receptor for hepatocyte growth factor; MMP: Matrix metalloproteinase; PG: Proteoglycan; RHAMM: Receptor for hyaluronan-mediated motility; RTK: Receptor tyrosine kinase; shRNA: short hairpin RNA; SLURP: Small leucine-rich proteoglycan; SPARC: Secreted protein, acidic and rich in cysteine; TAM: Tumour-associated macrophage; TGF-β: Transforming growth factor beta; TME: Tumour microenvironment; TN-C: Tenascin; TNF-α: Tumour necrosis factor α; VEGF: Vascular endothelial growth factor.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

AS and HJ equally contributed to writing and editing the manuscript. Both writers have read and approved the final manuscript.

Acknowledgements

Financially this study was supported by Medical Research Fund (EVO) of Turku University Hospital and Cancer Foundation of South-Western Finland.

Received: 6 February 2014 Accepted: 23 April 2014
Published: 2 May 2014

References

1. Hyres RO. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216–1219.
2. Järveläinen H, Sainio A, Koulu M, Wight TN, Penttinen R: Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009, 61:198–223.

3. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144:646–674.

4. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010, 123:4195–4202.

5. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196:395–406.

6. Fang H, Dedlerk YA: Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 2013, 73:4965–4977.

7. Sainio A, Järveläinen H. Extracellular matrix molecules in tumour microenvironment with special reference to desmoplastic reaction and the role of matrix proteoglycans and hyaluronan. J Carcinos Mutagen, in press.

8. Baikwili FR, Capasso M, Hagemann T: The tumor microenvironment at a glance. J Cell Sci 2012, 125:5591–5596.

9. Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumour Biol, in press.

10. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, Palmqvist R: The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012, 7:e47045.

11. Fridleender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SO, Bognár L, Hanzely Z, Kleiner A: Brevican, neurocan, tenascin-C and versican are highly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res 2012, 18:3–40.

12. Gordon MK, Hahn RA: Collagens. Cell Tissue Res 2010, 339:247–257.

13. Xiong G, Deng L, Zhu J, Rychahou PG, Xu R: Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer 2014, 14:1.

14. Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD: Expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathways. J Cell Biol 2015, 209:115–127.

15. Ye J, Wu D, Wu P, Chen Z, Huang J. The cancer stem cell niche: cross talk between cancer stem cells and their microenvironment. Tumour Biol, in press.

16. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, Palmqvist R: The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012, 7:e47045.

17. Fridleender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SO, Bognár L, Hanzely Z, Kleiner A: Brevican, neurocan, tenascin-C and versican are highly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res 2012, 18:3–40.

18. Gordon MK, Hahn RA: Collagens. Cell Tissue Res 2010, 339:247–257.

19. Xu L, Lu D, Scully M, Kakkar V: Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013, 34:2041–2051.

20. Xiong J, Balcisuglo HE, Danen EH: Integrin signaling in control of tumor growth and progression. Int J Biochem Cell Biol 2013, 45:1012–1015.

21. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58–61.

22. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:247–252.

23. Ingber DE, Folkman J: How does extracellular matrix control capillary morphogenesis? Cell 1989, 58:803–805.

24. Quail DF, Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423–1437.

25. Sage EH, Bornstein P: Extracellular proteins that modulate cell-matrix interactions. SPARC, tenasin, and thrombospondin. J Biol Chem 1991, 266:14831–14834.

26. Bornstein P: Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin I. J Cell Biol 1995, 130:503–506.

27. Bornstein P, Sage EH: Matricellular proteins: extracellular modulators cell function.Curr Opin Cell Biol 2002, 14:608–616.

28. Varga I, Hutozcky G, Szemcsák CD, Zahucky G, Toth J, Adamecz Z, Kenyeres A, Bogán L, Hanzely Z, Kleiner A: Brevican, neurocan, tenascin-C and versican are highly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res 2012, 18:3–40.

29. Wood SL, Pernemalm M, Crosbie PA, Whetton AD: Emerging role of tumor microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423–1437.

30. Jean MC, Youn J, Cheng GD, Xin D, Liu Y: Collagen as a dynamic-edged sword in tumor progression. Tumour Biol 2013, in press.

31. Quail DF, Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013, 19:1423–1437.

32. Sage EH, Bornstein P: Extracellular proteins that modulate cell-matrix interactions. SPARC, tenasin, and thrombospondin. J Biol Chem 1991, 266:14831–14834.

33. Bornstein P: Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin I. J Cell Biol 1995, 130:503–506.

34. Bornstein P, Sage EH: Matricellular proteins: extracellular modulators cell function. Curr Opin Cell Biol 2002, 14:608–616.

35. Varga I, Hutozcky G, Szemcsák CD, Zahucky G, Toth J, Adamecz Z, Kenyeres A, Bogán L, Hanzely Z, Kleiner A: Brevican, neurocan, tenascin-C and versican are highly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res 2012, 18:3–40.

36. Gordon MK, Hahn RA: Collagens. Cell Tissue Res 2010, 339:247–257.

37. Kuoppila S, Stenbäck F, Risteli J, Jukkola A, Risteli L: Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol 1998, 186:262–268.

38. Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG: Biochemical role of the collagen-rich tumor microenvironment in pancreatic cancer progression. Biochem J 2012, 441:541–552.

39. Fang M, Yuan J, Peng C, Li Y: Collagen as a dynamic-edged sword in tumor progression. Tumour Biol 2013, in press.

40. Xiong G, Deng L, Zhu J, Rychahou PG, Xu R: Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer 2014, 14:1.

41. Altowami S, Troup S, Al Haddad S, Kirkpatrick I, Watson PH: Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003, 5:R129–R135.

42. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254–265.

43. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vaises G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 90:289–298.

44. Frey N, Kufe D, Jonat W, Fietzek P, Huang J: Prognostic value of type XXII and XXIV collagen mRNA expression in head and neck cancer patients. Mol Biol Oncol 2014, 1:285–291.

45. Järveläinen H, Wight TN: Vascular proteoglycans. In Proteoglycans in Lung disease. Edited by Gang HG, Roughley PJ, Hales CA. New York: Marcel Dekker Inc; 2002:291–321.

46. Schafer L, Izzo RV: Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 2002, 278:3:1003–1039.

47. Izzo RV: The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Molec Biol 1997, 32:141–174.

48. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV: Amino Acids: Pharmacol Rev 2013, 58:4965–4977.

49. Varga I, Hutozcky G, Szemcsák CD, Zahucky G, Toth J, Adamecz Z, Kenyeres A, Bogán L, Hanzely Z, Kleiner A: Brevican, neurocan, tenascin-C and versican are highly responsible for the invasiveness of low-grade astrocytoma. Pathol Oncol Res 2012, 18:3–40.

50. Louis J, Jarronen H, Penttinen R: Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009, 61:198–223.
51. Goldberg M, Raoport O, Septier D, Palmer K, Hall R, Embery G, Young M, Ameye L: Proteoglycans in predentin: in the last 15 micrometers before mineralization. Connect Tissue Res 2003, 44(Suppl 1):184–188.

52. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RT, McQuillan DJ, Izzo RV: Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24(11):1104–1110.

53. Goldoni S, Seidler DG, Heath I, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, Izzo RV: An antimitotic role for decorin in breast cancer. Am J Pathol 2008, 173(4):848–855.

54. Bi X, Pohl NM, Qian Z, Yang G, Gu Y, Guzman G, Kajdacsy-Balla A, Iozzo RV, Yang W: Decorin-inhibited migration of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 2012, 33:325–330.

55. Goldoni S, Humphries A, Nytööm A, Sattar S, Owens RT, McQuillan DJ, Iretin K, Izzo RV: Decorin is a novel antagonist ligand of the Met receptor. J Cell Biol 2009, 185:734–754.

56. Izzo RV, Buraschi S, Genova M, Xu SQ, Solomides CC, Peiper SC, Gornella LG, Owens RC, Monti A: Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 2011, 286:34712–34721.

57. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV: Hyaluronan: A simple polysaccharide with diverse biological functions. Glycobiology 2000, 10:353–364.

58. Salomäki HH, Sainio AO, Söderström M, Pakkanen S, Laine J, Järveläinen HT: Stromal hyaluronan level is associated with poor differentiation and malignancy in breast cancer. J Histochem Cytochem 2006, 54(11):991–1001.

59. Brézillon S, Pietraszek K, Maquart FX, Wegrowski Y: Lumican in the control of tumour progression and their links with metalloproteinases and integrins. FEBS Lett 2013, 280:2369–2381.

60. Nikitovic D, Papoutsidakis A, Karamanos NK, Tzanakakis GN: Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response. Matrix Biol, in press.

61. Craig EA, Parker P, Camenisch TD: Decorin-induced inhibition of colorectal cancer growth and malignant cells associates with breast cancer spreading and metastasis. Cancer Lett 2010, 291:59–66.

62. Dicker KT, Gurski LA, Pradhan-Bhatt S, Witt RL, Farach-Carson MC, Jia X: Antimetastatic role for decorin in breast cancer cells. J Mammary Gland Biol Neoplasia 2013, 18(1):363–372.

63. Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, Kosma VM: Hyaluronan antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J Biol Chem 2003, 278:42125–42133.

64. McQuillan DJ, Iozzo RV: Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules. Cur Med Res 2012, 28(2):1068–1082.

65. Chen N, Karantza-Wadsworth V: Role and regulation of autophagy in cancer. Biochim Biophys Acta 2009, 1793:1516–1523.

66. Mathew R, Karp CM, Beaudin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhout G, Gelinas C, Dipacka RS, Karantza-Wadsworth V: White E: Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062–1075.

67. Neill T, Torres A, Buraschi S, Izzo RV: Decorin has an appetite for endothelial cell autophagy. Autophagy 2013, 9:1626–1628.

68. Buraschi S, Neill T, Goyal A, Poluzzi C, Smythies J, Owens RT, Schafer L, Torres A, Izzo RV: Decorin causes autophagy in endothelial cells via Peg3. PLoS One 2013, 11:12554–E2591.

69. Neill T, Torres A, Buraschi S, Hoek JB, Baffa R, Izzo RV: Decorin induces mitophagy in breast carcinoma cells via PGC-1a and mitostatin. J Biol Chem, in press.

70. Micalizzi DS, Farabaugh SM, Ford HL: Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15:117–134.

71. Trimbori AI, Fukino K, de Bruin A, Wei Q, Shen L, Tanner SM, Creasap N, Rosol TJ, Robinson ML, Eng C, Ostrowski MC, Leone G: Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 2008, 68:937–945.

72. Verspieren D, Groop M, Hauk F, Dënizel F, Fahn S, Hagedorn M, Jörnvall H: A novel concept of breast cancer epithelial-mesenchymal transition. Carcinogenesis 2009, 30:1516–1522.

73. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J: Breast cancer cells produce tenasin-C as a metastatic niche component to colonize the lungs. Nat Med 2011, 17:967–974.

74. Maschler S, Gruner S, Danielopoulos A, Beug H, Wirt G: Enhanced tenasin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells. Oncogene 2004, 23:3622–3633.

75. Katoh D, Nagaharu K, Shimojo N, Hanamura N, Yamashita M, Kozuka Y, Imanaka-Yoshida K, Yoshida T: Binding of αβ1 and αβ6 integrins to tenasin-C splice variants in breast cancer progression. Am J Pathol 2003, 162:1857–1867.

76. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J: Breast cancer cells produce tenasin-C as a metastatic niche component to colonize the lungs. Nat Med 2011, 17:967–974.

77. Maschler S, Gruner S, Danielopoulos A, Beug H, Wirt G: Enhanced tenasin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells. Oncogene 2004, 23:3622–3633.

78. Kato T, Nakanishi N, Shimojo N, Hanamura N, Yamashita M, Kozuka Y, Imanaka-Yoshida K, Yoshida T: Binding of αβ1 and αβ6 integrins to tenasin-C splice variants in breast cancer progression. Am J Pathol 2003, 162:1857–1867.

79. Wirth T, Parker N, Ylä-Herttuala S: History of gene therapy. Science 2013, 340:147–155.

80. Provenzano PP, Cuevas C, Chang AE, Geel VK, Von Hoff DD, Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418–429.

81. Miele CT: Endothelial cell’s biomechanical properties are regulated by invasive cancer cells. Mol Biol Cell 2012, 8:1639–1649.

82. Miele CT: Physical break-down of the classical view on cancer cell invasion and metastasis. Eur J Cell Biol 2013, 92:99–104.

83. Densai C, Lammerding J: Nuclear mechanics in cancer. Adv Exp Med Biol 2014, 773:435–440.

84. Zou X, Feng B, Dong T, Yan G, Tan B, Shen H, Huang A, Zhang X, Zhang M, Yang P, Zheng M, Zhang Y: Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis. J Proteomics 2013, 94:473–485.
97. Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, de Paula CA, Mader AM, Waisberg J, Pinhal MA, Friedl A, Toma L, Nader HB: Colorectal cancer desmoplastic reaction up-regulates collagen synthesis and restricts cancer cell invasion. Cell Tissue Res 2011, 346:223–236.

98. Karagianis GS, Petrali C, Prassas I, Sarac P, Musrap N, Dimitrromanolis A, Diamandis EP: Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis. Oncotarget 2012, 2:267–285.

99. Merika EE, Syrigos KN, Salf MW: Desmoplasia in pancreatic cancer. Can we fight it? Gastroenterol Res Pract 2012, 2012:781765.

100. Whatcott CJ, Posnur RG, Von Hoff DD, Han H: Desmoplasia and chemoresistance in pancreatic cancer. In Pancreatic Cancer and Tumor Microenvironment. Edited by Grigopo PJ, Munshi KG. Trivandrum: Transworld Research Network; 2012. Chapter 8.

101. Kucabagouli P, Friedman SL: Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci (Schol Ed) 2013, 5:217–230.

102. Choi IK, Strauss R, Richter M, Yun CO, Lieber A: Strategies to increase drug penetration in solid tumors. Front Oncol 2013, 3:193.

103. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497–2503.

104. McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi M: Hyaluronidase expression by an oncolytic adenovirus enhances its penetration in solid tumors. Front Oncol 2013, 3:1809.

105. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK: Strategies for advancing cancer nanomedicine. Nat Mater 2013, 12:958–962.

106. Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA: Pretreatment with protease is a useful experimental strategy for enhancing adeno-virus-mediated cancer gene therapy. Hum Gene Ther 2000, 11:2219–2230.

107. Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA: Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res 2001, 61:1805–1809.

108. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R: Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010, 18:1275–1283.

109. McBride WH, Bard JB: Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med 1979, 149:507–515.

110. Zyuz’kov GN, Zhdanov VW, Dygai AM, Gol’dberg ED: Role of hyaluronidase in the regulation of hemopoiesis. Bull Exp Biol Med 2007, 144:840–845.

111. Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52–67.

112. Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN, Hay JG: Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007, 15:1982–1990.

113. Brown E, McKee T, di Tomaso E, Pluen A, Boucher Y, Jain RK: Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003, 9:796–800.

114. Diop-Frimpong B, Chauhan VP, Kraene S, Boucher Y, Jain RK, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 2011, 108:2909–2914.

115. Tralhão JS, Schaefer L, Micogeva M, Evaristo C, Schönher C, Kayal S, Veiga-Fernandes H, Daniel C, Iazo RV, Kruse H, Lemarchand P: In vivo selective and distant killing of cancer cells using adeno-virus-mediated decorin gene transfer. FASEB J 2003, 17:464–466.

116. Bostrom P, Sainio A, Kakko T, Savontaus M, Söderström M, Järveläinen H: Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast. Histochem Cell Biol 2013, 139:161–171.

117. Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, Andrade de Paula CA, Carneiro CR, Ortiz V, Toma L, Xiao WW, Nader HB: Lumican expression, localization and its tumor activity in prostate-cancer. Exp Cell Res 2013, 319:697–698.

118. de Wit M, Belt DJ, Delis-van Diemen PM, Carvalho B, Coupé VM, Stockmann HB, Brill H, Bellén JA, Fijneman RJ, Meijer GA: Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann Surg Oncol 2013, 20(Suppl 5):S358–S359.

119. Petraszek K, Brezillon S, Perreau C, Malicka-Błąskiewicz M, Maquart FX, Wogrowski Y: Lumican - derived peptides inhibit melanoma cell growth and migration. PLoS One 2013, 8:e76032.

120. He ZH, Lei Z, Zhen Y, Gong W, Huang B, Yuan Y, Zhang GM, Wang XJ, Feng ZH: Hyaluronan-associated virus-mediated expression of recombinant CBD-Hepl polypeptide of human fibronectin inhibits metastasis of breast cancer. Breast Cancer Res Treat 2014, 143:31–41.

121. Mitra S, Heldin P, Haskell VC, Karamanos NK, Skandalis SS, Markwald RR, Ghatak S: Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011, 278:1429–1443.

122. Mitra S, Haskell VC, De Giovanni C, Markwald RR, Ghatak S: Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+MICE. J Biol Chem 2009, 284:12342–12346.

123. Seppinen L, Pihlajaniemi T: The multiple functions of collagen XVIII in development and disease. Matrix Biol 2011, 30:83–92.

124. Pan JG, Luo RX, Zhou X, Han RF, Zeng GW: Potent antitumor activity of the combination of HSV-TK and endostatin by adeno-associated virus vector for bladder cancer in vivo. Clin Lab 2013, 59:1147–1158.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit